Inflammation in Coronary Microvascular Dysfunction

Area of Science:

• Cardiovascular Medicine
• Inflammation Research
• Vascular Biology

Background:

• Chronic low-grade inflammation is a key factor in coronary atherosclerosis.
• Coronary microvascular dysfunction (CMD) involves abnormalities in small vessels (<500 μm), impairing myocardial oxygen supply.
• CMD manifests across a spectrum of cardiovascular conditions, from stable angina to heart failure and sudden cardiac death.

Purpose of the Study:

• To review the pathogenesis of coronary microvascular dysfunction.
• To evaluate non-invasive screening methods for detecting CMD.
• To explore the potential of anti-inflammatory agents as therapeutic strategies for CMD in atherosclerotic heart disease.

Main Methods:

• Literature review focusing on pathogenesis and diagnostic methods for CMD.
• Analysis of recent clinical assessments of anti-inflammatory and immunomodulatory agents.
• Synthesis of evidence regarding the role of inflammation in CMD and its treatment.

Main Results:

• CMD pathogenesis involves structural and functional abnormalities of coronary microvessels, leading to inadequate oxygen delivery.
• Non-invasive screening methods show capability in detecting CMD.
• Anti-inflammatory agents (statins, anakinra, tocilizumab, TNF-α inhibitors) are being assessed for therapeutic potential.

Conclusions:

• CMD is a significant contributor to cardiovascular events in atherosclerotic heart disease.
• Targeting inflammation with agents like statins and immunomodulators may offer new treatment avenues.
• Further research into anti-inflammatory therapies is warranted to reduce cardiovascular events associated with CMD.